Sobi to Present Clinical Data on Gamifant at Histiocyte Society Meeting
What happened
Sobi announced that new clinical data regarding Gamifant (emapalumab) for primary haemophagocytic lymphohistiocytosis (HLH) will be presented at the 2026 Annual Meeting of the Histiocyte Society (HS2026). The presentations will take place in Rotterdam, from September 26 to 29, 2026. The accepted abstracts include a new pooled analysis of pre- and post-transplant survival outcomes across three prospective trials, along with data from a post-authorisation study in treatment-experienced Chinese patients.
From prnewswire.com
Why it matters
The company is continuing to build evidence regarding treatment and transplant outcomes in primary HLH. The pooled analysis was selected as one of the ten highest-scoring poster abstracts and was nominated for the Robert J. Arceci Prize for Best Poster.
From prnewswire.com
Who's involved
- Histiocyte SocietyThe society is hosting the major international conference where the clinical data will be presented.
- RotterdamThe city where the annual meeting of the Histiocyte Society will be held.
- North AmericaThe continent where Sobi has a market presence relevant to the drug being discussed.
Keep exploring
The entities involved
-
Rotterdam
city in South Holland, the Netherlands